Autolus Therapeutics plc 8-K

What Happened
Autolus Therapeutics plc announced its financial results for the year ended December 31, 2025 and provided a corporate update in an 8‑K filed March 27, 2026. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), which it used in a March 27, 2026 conference call to discuss the results (Regulation FD disclosure).

Key Details

• Filing date: March 27, 2026; reporting period: year ended December 31, 2025.
• Press release announcing results furnished as Exhibit 99.1; corporate presentation used on the conference call furnished as Exhibit 99.2.
• Conference call on March 27, 2026 utilized the updated presentation (Regulation FD disclosure).
• Form 8‑K was signed by CEO Christian Itin, Ph.D.

Why It Matters
This 8‑K makes Autolus’s full-year 2025 financial results and corporate outlook publicly available and confirms the materials presented on the company’s earnings call. Investors should review the furnished press release and presentation for the actual earnings, revenue, cash position, and management commentary to assess near‑term prospects and valuation. The Regulation FD disclosure indicates the company intentionally used the updated presentation during its public call to ensure broad, simultaneous dissemination of material information.